

# Stefan Andreas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9057142/publications.pdf>

Version: 2024-02-01

31  
papers

1,279  
citations

686830

13  
h-index

414034

32  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1668  
citing authors

#	ARTICLE	IF	CITATIONS
1	COPD mortality and exacerbations in the placebo group of clinical trials over two decades: a systematic review and meta-regression. <i>ERJ Open Research</i> , 2022, 8, 00261-2021.	1.1	3
2	Non-typeable <i>Haemophilus influenzae</i> "Moraxella catarrhalis" vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 435-446.	5.2	16
3	Smoking cessation by combined medication and counselling: a feasibility study in lung cancer patients. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	1
4	miR449 Protects Airway Regeneration by Controlling AURKA/HDAC6-Mediated Ciliary Disassembly. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7749.	1.8	1
5	Update on recent key publications in lung oncology: picking up speed. <i>European Respiratory Review</i> , 2021, 30, 200300.	3.0	1
6	Three-dimensional assessment of bronchiectasis in a mouse model of mucociliary clearance disorder. <i>ERJ Open Research</i> , 2021, 7, 00635-2020.	1.1	1
7	<p>Effects of LAMA/LABA Alone and in Combination on Cardiac Safety</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1931-1933.	0.9	1
8	<p>No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1945-1953.	0.9	4
9	<p>Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1935-1944.	0.9	2
10	&lt;p&gt;A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD&lt;/p&gt;. <i>International Journal of COPD</i> , 2020, Volume 15, 1955-1965.	0.9	4
11	Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. <i>European Respiratory Journal</i> , 2020, 56, 1902279.	3.1	102
12	Inhaled therapy reduces COPD mortality. <i>ERJ Open Research</i> , 2020, 6, 00634-2020.	1.1	13
13	Decline of COPD exacerbations in clinical trials over two decades " a systematic review and meta-regression. <i>Respiratory Research</i> , 2019, 20, 186.	1.4	10
14	&lt;p&gt;Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort&lt;/p&gt;. <i>International Journal of COPD</i> , 2019, Volume 14, 2163-2172.	0.9	35
15	Transcription factor Tap73 and microRNA-449 complement each other to support multiciliogenesis. <i>Cell Death and Differentiation</i> , 2019, 26, 2740-2757.	5.0	26
16	Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. <i>Respiratory Medicine</i> , 2018, 137, 14-22.	1.3	35
17	Economic burden of resected (stage IB-IIIa) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). <i>Lung Cancer</i> , 2018, 124, 298-309.	0.9	34
18	The association of cardiovascular autonomic dysfunction and the prediction of COPD can be explained by neurohumoral activation. <i>European Respiratory Journal</i> , 2018, 51, 1800737.	3.1	1

#	ARTICLE	IF	CITATIONS
19	Effect of long-acting $\beta_2$ -agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 52, 1-6.	1.1	9
20	Adjuvant treatment patterns and outcomes in patients with stage IB-IIIa non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. <i>Lung Cancer</i> , 2018, 124, 310-316.	0.9	27
21	Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. <i>Respiratory Research</i> , 2017, 18, 139.	1.4	135
22	Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?. <i>ERJ Open Research</i> , 2016, 2, 00055-2016.	1.1	2
23	Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data. <i>Biometrical Journal</i> , 2016, 58, 170-185.	0.6	9
24	Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. <i>European Respiratory Journal</i> , 2015, 46, 186-196.	3.1	194
25	Inhaled $\beta_2$ -agonist does not modify sympathetic activity in patients with COPD. <i>BMC Pulmonary Medicine</i> , 2015, 15, 46.	0.8	12
26	Increased Sympathetic Nerve Activity in COPD is Associated with Morbidity and Mortality. <i>Lung</i> , 2014, 192, 235-241.	1.4	57
27	Long-Acting Bronchodilators and Arterial Stiffness in Patients With COPD. <i>Chest</i> , 2014, 146, 1521-1530.	0.4	27
28	Effectiveness of Varenicline as an Aid to Smoking Cessation in Primary Care: An Observational Study. <i>European Addiction Research</i> , 2013, 19, 47-54.	1.3	13
29	Exercise intolerance and systemic manifestations of pulmonary emphysema in a mouse model. <i>Respiratory Research</i> , 2009, 10, 7.	1.4	59
30	Neurohumoral Activation as a Link to Systemic Manifestations of Chronic Lung Disease. <i>Chest</i> , 2005, 128, 3618-3624.	0.4	205
31	Marked Sympathetic Activation in Patients with Chronic Respiratory Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 597-601.	2.5	239